PRTA News and Press, Prothena Corporation plc From 11/02/23

2023-11-02 16:14:22 ET More on Prothena Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise Prothena (PRTA) Investor Presentation - Slideshow Prothena, BioVie among decliners after Biogen data for new Alzheimer’s therapy Prothena ...

Net cash provided by operating and investing activities was $9.1 million in the third quarter and net cash used in operating and investing activities was $84.1 million for the first nine months of 2023; quarter-end cash and restricted cash position was $673.1 million Received $55 million paym...

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

Prothena Corporation plc (PRTA) is expected to report $-0.26 for Q3 2023

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its third quarter and first nine months of 2023 financial results on Thursday, N...

2023-10-26 13:48:39 ET More on BioVie, Cognition, etc. BioVie: Bullish Signals From Blinded Data Presentation (Rating Upgrade) Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise BioVie: Well-Powered Phase 3 Trial In Alzheimer's Could Greatly Be...

2023-10-26 09:56:33 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector as earnings close in BofA reports 10th consecutive week of equity inflows For further detail...

2023-10-16 09:48:02 ET More on Prothena Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise Prothena (PRTA) Investor Presentation - Slideshow Prothena: Dunn Appointment And Bristol Opt-In Boost Validation Alzheimer's drug developers get ...

2023-10-13 13:05:06 ET A national policy that limited the use of a type of brain scan called positron emission tomography (PET) in testing for symptoms of Alzheimer's disease has been removed, the U.S. Centers for Medicare & Medicaid Services (CMS) said on Friday. The cause of the m...

2023-09-21 13:39:18 ET Summary Prothena Corporation is a protein dysregulation specialist with a focus on developing drugs for Alzheimer's disease. The company's lead candidate, PRX012, is an amyloid clearing drug that is currently in Phase 1 clinical trials. Prothena also has...